Healthcare / BiotechnologyTokyo
$688.00
-13.00 (-1.85%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-929.2M · quality 60.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
10/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$8.0B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-78.5%
↓Gross Margin
N/A
•Debt/Equity
1.19
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.94x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-993.2M · FCF $-929.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | $1.00B | — |
| Net Income | $-993.2M | $-993.2M | $-846.5M | $260.3M | $-392.4M |
| EBITDA | $-987.2M | $-987.2M | $-844.1M | $366.1M | $-353.8M |
| EPS | — | — | -72.94 | 23.07 | -42.06 |
| Gross Margin | — | — | — | 91.0% | — |
| Operating Margin | — | — | — | 36.6% | — |
| Net Margin | — | — | — | 26.0% | — |
| Balance Sheet | |||||
| Debt/Equity | 1.19 | 1.19 | — | — | — |
| Current Ratio | 20.88 | 20.88 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-929.2M | $-929.2M | $-998.2M | $444.6M | $-393.4M |
| Returns | |||||
| ROE | -78.5% | -78.5% | -37.5% | 8.4% | -29.4% |
| Valuation | |||||
| P/E | — | — | — | 30.04 | — |
| EV/EBITDA | — | — | — | 12.44 | — |
| P/B | 6.31 | 6.31 | 3.19 | 2.52 | — |
| Growth & Yield | |||||
| EPS Growth | — | — | -416.2% | 154.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-11.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-72.94 → n/d
Residual
-11.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.